News

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...
A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...
Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...
Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...
Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.
Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...
China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...
Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.